Hereditary angioedema market

Hereditary Angioedema Market, by Drug Class (C1 Esterase Inhibitor, Kallikrein Inhibitor, Bradykinin Receptor, Attenuated Androgens, and Others), by Route of Administration (Subcutaneous, Intravenous, and Oral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and e-Commerce), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Jul 2022
CMI1292
175 Pages
Excel & Pdf
Pharmaceutical

Summary

Hereditary angioedema (HAE) is a rare disorder related to the immune system. The life-threatening condition is caused due to the lack of C1-esterase inhibitor (C1-INH) causing the blood vessels to dilate. The symptoms of the disease include recurrent episodes of edema in various body parts such as hands, feet, face and airways. HAE is classified into 3 types: Type I HAE, Type II HAE and Type III HAE based on the reduction in its synthesis of inhibitor or the formation of a dysfunctional protein. Although, the condition is hereditary, the absence of a family history does not rule out the diagnosis of HAE, indicating that as many as 25% of HAE cases result from a spontaneous mutation of the C1-inhibitor gene at conception.

Global hereditary angioedema market is estimated to be valued at US$ 2,431.89 million in 2022 and is expected to exhibit a CAGR of 9.1% during the forecast period (2022-2030)

Figure 1.Global Hereditary Angioedema Market Share (%), by Distribution Channel, 2022

Increasing prevalence and rising awareness of hereditary angioedema are expected to drive growth of the hereditary angioedema market.

Increasing number of hereditary angioedema cases and the hereditary nature giving the disease an ability to pass the defective gene to the future generations is expected to propel market growth. For instance, according to an article published by the National Center for Biotechnology Information, in May 2022, the estimated prevalence of hereditary angioedema is 1 in 50,000 worldwide. Also according to the National Organization for Rare Disorders (NORD), the risk of passing the abnormal gene from affected parent to offspring is 50% for each pregnancy regardless of the sex of the resulting child.

Hereditary Angioedema Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 2,431.89 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	9.1%	2030 Value Projection:	US$ 4,897.51 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Drug Class: C1 Esterase Inhibitor, Kallikrein Inhibitor, Bradykinin Receptor, Attenuated Androgens, Others By Route of Administration: Subcutaneous, Intravenous, Oral By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, e-Commerce
Companies covered:	CSL Behring, Takeda Pharmaceutical Company Limited., Pharming, BIOCRYST PHARMACEUTICALS, INC., Ionis Pharmaceuticals, Inc., Attune Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., KalVista Pharmaceuticals, CENTOGENE N.V., and Sanofi
Growth Drivers:	Increasing prevalence and rising awareness of hereditary angioedema Increasing support from non-profit organizations towards intensive research
Restraints & Challenges:	Possibility of misdiagnosis of hereditary angioedema High cost of drugs used for angioedema treatment

Figure 2.Global Hereditary Angioedema Market Share (%), by Region, 2022

Increasing support from non-profit organizations towards intensive research are expected to drive the market growth during the forecast period.

The organizations are focusing on increasing global hereditary angioedema (HAE) awareness by educating and empowering patients and providing access to suitable therapy/treatment. The organizations are also working towards intensive research to find a cure for hereditary angioedema. For instance, the non-profit organization named HAEi is dedicated towards spreading awareness of C1-inhibitor deficiencies and to improve diagnosis, facilitating access to reimbursement of the HAE therapies, enabling lifelong health for the global patients. Moreover, the non-profit organization, US Hereditary Angioedema Association is committed to advance and conduct clinical research designed to improve the condition of HAE patients

Global Hereditary Angioedema Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

The COVID-19 pandemic had a negative impact on the hereditary angioedema market, owing to the disruption in the treatment of hereditary angioedema. For instance, according to an article published by the National Center for Biotechnology Information, in January 2022, online global surveys to capture patient and health-care professional (HCP) perspectives on the impact that COVID-19 has had, and the future impact it will have on hereditary angioedema (HAE) medical care was carried out. As per the outcomes, both patients and HCPs globally reported that the pandemic had limited the availability of HAE medical care, and they expect the restrictions to continue far beyond the pandemic. Moreover, patients and HCPs expect that HAE-related care will be negatively impacted by the pandemic for several years. Disparities in medical care and technologic infrastructure may exacerbate these challenges in non–high-income countries. Supportive tools and global infrastructure should be established to provide aid to non–high-income countries throughout the pandemic and several years after.

Global Hereditary Angioedema Market: Key Developments

On June 7, 2022, BioCryst Pharmaceuticals, Inc., a company that designs and develops small molecule medicines for rare diseases such as hereditary angioedema (HAE) and fibrodysplasia ossificans progressive (FOP), announced that Swissmedic, the Swiss surveillance authority for medicines and medical devices, had granted marketing authorization for oral, once-daily ORLADEYO (berotralstat) for the routine prevention of recurrent hereditary angioedema (HAE) attacks in patients 12 years and older in Switzerland

In March 2022, Ionis Pharmaceuticals, Inc., a biotechnology company, announced the publication of positive Phase 2 data for donidalorsen in the New England Journal of Medicine (NEJM). Donidalorsen is an investigational antisense medicine that Ionis Pharmaceuticals, Inc., is evaluating for treating patients with hereditary angioedema (HAE). In the Phase 2 study, donidalorsen demonstrated a 90% reduction in angioedema attacks compared with placebo at the 80 mg monthly dose. There was significant improvement in quality of life as assessed by the Angioedema Quality of Life Questionnaire (AE-QoL) in the patients treated with donidalorsen.

Global Hereditary Angioedema Market: Restraint

The major factors that hinder growth of the global hereditary angioedema market include possibility of misdiagnosis of hereditary angioedema and high cost of drugs used for angioedema treatment. For instance, according to an article published by Everyday Health, Inc., in June 2020, people with hereditary angioedema (HAE) are often misdiagnosed as having another medical problem. According to the same source, in a survey of 313 patients, 65 percent of those with HAE reported being misdiagnosed before a doctor accurately identified their condition. HAE is commonly mistaken for an allergic reaction, appendicitis, and irritable bowel syndrome (IBS). About 40 percent of people with HAE are diagnosed within the first three years whereas almost 33 percent of people still face delays of 10 years or longer

Key Players

Major players operating in the global hereditary angioedema market include CSL Behring, Takeda Pharmaceutical Company Limited., Pharming, BIOCRYST PHARMACEUTICALS, INC., Ionis Pharmaceuticals, Inc., Attune Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., KalVista Pharmaceuticals, CENTOGENE N.V., and Sanofi

Table of Content

Table of Contents

*Browse 58 market data tables and 32 figures on "Hereditary Angioedema Market” - Global forecast to 2030

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global hereditary angioedema market during the forecast period (2022-2030)?

The global hereditary angioedema market size is estimated to be valued at US$ 2,431.89 million in 2022 and is expected to exhibit a CAGR of 9.1% between 2022 and 2030.

What are the major factors driving the market growth?

Factors such as increasing prevalence and rising awareness of hereditary angioedema and increasing support from non-profit organizations towards intensive research are expected to drive the market growth.

Which is the leading drug class segment in the market?

C1 esterase inhibitor is the leading drug class segment in the market.

What are the key factors hampering growth of the market?

The major factors hampering growth of the market include possibility of misdiagnosis of hereditary angioedema and high cost of drugs used for angioedema treatment.

Which are the major players operating in the market?

Major players operating in the market include CSL Behring, Takeda Pharmaceutical Company Limited., Pharming, BIOCRYST PHARMACEUTICALS, INC., Ionis Pharmaceuticals, Inc., Attune Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., KalVista Pharmaceuticals, CENTOGENE N.V., and Sanofi.